Evidence map›Paper›PMID 39428537›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab.

Takashi Matsumura, Kenji Tsuchihashi, Takeo Yamamoto, Fumiaki Jinnouchi, Wataru Kusano, Yota Kusumoto, Kohei Arimizu, Hirofumi Ohmura, Yuki Kuma, Shohei Moriyama and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takashi MatsumuraDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Kenji TsuchihashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Takeo YamamotoDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Japan.
Fumiaki JinnouchiDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Wataru KusanoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Yota KusumotoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Kohei ArimizuDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Hirofumi OhmuraDepartment of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan.
Yuki KumaDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Japan.
Shohei MoriyamaDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Kyoko YamaguchiDepartment of Medical Education, Graduate School of Medical Science, Kyushu University, Japan.
Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Taichi IsobeDepartment of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan.
Hiroshi AriyamaDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Yoshinao OdaDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Japan.
Koichi AkashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Japan.
Eishi BabaDepartment of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalEsophageal NeoplasmsLymphoproliferative DisordersAgedAntineoplastic Combined Chemotherapy ProtocolsEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansLung NeoplasmsMaleRituximabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabRituximabEBVimmune checkpoint inhibitorlymph proliferative disorderspembrolizumab

Identifiers

PMID39428537
PMCPMC12222906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.